Brokerages Set Rallybio Corporation (NASDAQ:RLYB) Target Price at $5.00

Rallybio Corporation (NASDAQ:RLYB) has received a consensus rating of “Reduce” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $5.00.

Several research firms have commented on RLYB. Wall Street Zen upgraded shares of Rallybio from a “sell” rating to a “hold” rating in a research note on Saturday, October 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Rallybio in a research note on Wednesday.

Rallybio Stock Down 3.9%

NASDAQ:RLYB opened at $0.55 on Friday. The company has a fifty day simple moving average of $0.57 and a two-hundred day simple moving average of $0.44. The company has a market cap of $23.13 million, a price-to-earnings ratio of -0.59 and a beta of -1.10. Rallybio has a 52 week low of $0.22 and a 52 week high of $1.24.

Rallybio (NASDAQ:RLYB) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.02. The business had revenue of $0.21 million during the quarter. Rallybio had a negative net margin of 5,473.33% and a negative return on equity of 71.66%. On average, analysts expect that Rallybio will post -1.34 EPS for the current year.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.